
|Articles|May 8, 2018
The Missing Link in Amazon’s Healthcare Takeover
Author(s)Michelle Maskaly
John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries.
Advertisement
John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries, talks about what they are doing now, and the key element that is missing. His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026
2
How 3D Printing Speeds Up Drug Production
3
Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts
4
FDA Pilot Targets Faster Early-Stage Drug Trial Starts
5




